Targets › MECP2
3 programs from 3 companies in 5 trials: 3 Phase 3, 2 Phase 1; Neurology, Psychiatry; next expected readout Sep 2027.
Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. (UniProt, P51608)
Open in Phaseline: the race on MECP2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Taysha Gene Therapies | TSHA-102 recombinant, non-replicating, self-complementary AAV9 vector encoding miniMECP2 gene, deli | MECP2 | Phase 3 | Rett Syndrome | Nov 2028 |
| Neurogene | NGN-401 Recombinant AAV9 carrying full-length human MECP2 transgene | MECP2 | Phase 3 | Rett Syndrome | Dec 2029 |
| Ionis Pharmaceuticals | ION440 Antisense oligonucleotide targeting MECP2 | MECP2 | Phase 1 | Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome | Sep 2027 |
Rett Syndrome (4) Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (1)
other (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.